Clinically relevant VAS pain score change in patients with acute rheumatic conditions

Abstract Introduction Pain assessment is a crucial step in the management of patients with rheumatic diseases. Among validated pain scores, the visual analog scale (VAS) score is the most widely used, in both clinical practice and therapeutic trials. Objective To determine the VAS pain score decreas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2007-07, Vol.74 (4), p.358-361
Hauptverfasser: Grilo, Rose Marie, Treves, Richard, Preux, Pierre Marie, Vergne-Salle, Pascal, Bertin, Philippe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Introduction Pain assessment is a crucial step in the management of patients with rheumatic diseases. Among validated pain scores, the visual analog scale (VAS) score is the most widely used, in both clinical practice and therapeutic trials. Objective To determine the VAS pain score decrease that constitutes meaningful pain relief, with the goal of evaluating treatment effects. Methods We included patients with acute pain caused by non-malignant rheumatic conditions. Pain duration of less than 1 month and a baseline VAS score greater than 50/100 mm were required. Twice daily, patients evaluated pain intensity using the VAS and pain relief using a five-category verbal rating scale (VRS) where 0 indicated no pain relief and 4 excellent relief. Results Fifty patients were included. VAS score changes correlated linearly with VRS score changes ( r = 0.7 and P < 0.001). A one-category improvement on the VRS was associated with a 20-mm decrease in the VAS score ( P < 0.0001) and a two-category improvement with a 40-mm decrease ( P < 0.0003). Conclusion The dearth of published data on clinically relevant VAS pain score changes in patients with acute rheumatic pain requires further studies, in order to improve patient care and the comparability of therapeutic trials.
ISSN:1297-319X
1778-7254
DOI:10.1016/j.jbspin.2006.06.019